Elysium Health Basis NAD+ Supplement Investigation

Migliaccio & Rathod LLP is investigating Elysium Health and its Basis NAD+ supplement, which is marketed as “clinically proven” to raise NAD+ levels and commonly linked to healthy-aging messaging.

Reported Issues

Consumers report:

  • Reliance on “clinically proven” marketing language
  • Billing, cancellation, and refund disputes
  • Subscription-management difficulties
  • Confusion between Elysium Health Basis NAD+ supplement increase claims and broader health implications

Why Consumers Should Be Concerned

Potential legal theories include:

  • Deceptive advertising, if clinical claims are overstated or implied beyond evidence
  • Negative-option billing issues
  • Unjust enrichment tied to disputed subscriptions

Signs You May Be Affected

  • Purchased Elysium Health on subscription
  • Had difficulty canceling or obtaining refunds
  • Relied on clinical or healthy-aging representations

If you have concerns that you have been affected by this and/or have experienced suspicious activity recently, we would like to hear from you. Please complete the contact form on this page, send us an email at [email protected], or give us a call at (202) 470-3520.

    The following will ask for your contact information so that we may reach you to talk about potential claims. This information is for our records only and will not be shared. By continuing, you consent to the collection of this information for these limited purposes.

    When did you last purchase this product (month and year)?
    Do you have proof of purchase for the product (receipt, email confirmation, transaction on your bank statement, etc.)?

    Please briefly describe the issue with the product.

    Would you like to join our newsletter to receive notifications about other investigations we're looking into, as well as updates on ongoing cases?

    The form will ask for your contact information so that we may reach you to talk about potential claims. This information is for our records only and will not be shared. By continuing, you consent to the collection of this information for these limited purposes.